Logo image of LVTX

LAVA THERAPEUTICS NV (LVTX) Stock Price, Quote, News and Overview

NASDAQ:LVTX - Nasdaq - NL0015000AG6 - Common Stock - Currency: USD

1.31  +0.08 (+6.5%)

After market: 1.3398 +0.03 (+2.27%)

LVTX Quote, Performance and Key Statistics

LAVA THERAPEUTICS NV

NASDAQ:LVTX (4/17/2025, 8:00:00 PM)

After market: 1.3398 +0.03 (+2.27%)

1.31

+0.08 (+6.5%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.2
52 Week Low0.85
Market Cap34.47M
Shares26.31M
Float15.69M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-19 2025-05-19
IPO03-29 2021-03-29


LVTX short term performance overview.The bars show the price performance of LVTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

LVTX long term performance overview.The bars show the price performance of LVTX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of LVTX is 1.31 USD. In the past month the price increased by 0.77%. In the past year, price decreased by -51.66%.

LAVA THERAPEUTICS NV / LVTX Daily stock chart

LVTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.09 306.02B
AMGN AMGEN INC 13.99 149.08B
GILD GILEAD SCIENCES INC 22.68 130.32B
VRTX VERTEX PHARMACEUTICALS INC 1686.55 125.74B
REGN REGENERON PHARMACEUTICALS 12.34 61.56B
ARGX ARGENX SE - ADR 318.82 36.23B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.51B
ONC BEIGENE LTD-ADR N/A 24.88B
BNTX BIONTECH SE-ADR N/A 23.74B
NTRA NATERA INC N/A 20.02B
SMMT SUMMIT THERAPEUTICS INC N/A 18.15B
BIIB BIOGEN INC 7.2 17.36B

About LVTX

Company Profile

LVTX logo image LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 37 full-time employees. The company went IPO on 2021-03-29. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Company Info

LAVA THERAPEUTICS NV

Yalelaan 60

Utrecht UTRECHT NL

Employees: 37

Company Website: https://www.lavatherapeutics.com/

Investor Relations: http://ir.lavatherapeutics.com/

Phone: 31630003035

LAVA THERAPEUTICS NV / LVTX FAQ

What is the stock price of LAVA THERAPEUTICS NV today?

The current stock price of LVTX is 1.31 USD. The price increased by 6.5% in the last trading session.


What is the ticker symbol for LAVA THERAPEUTICS NV stock?

The exchange symbol of LAVA THERAPEUTICS NV is LVTX and it is listed on the Nasdaq exchange.


On which exchange is LVTX stock listed?

LVTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LAVA THERAPEUTICS NV stock?

10 analysts have analysed LVTX and the average price target is 1.87 USD. This implies a price increase of 42.75% is expected in the next year compared to the current price of 1.31. Check the LAVA THERAPEUTICS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LAVA THERAPEUTICS NV worth?

LAVA THERAPEUTICS NV (LVTX) has a market capitalization of 34.47M USD. This makes LVTX a Nano Cap stock.


How many employees does LAVA THERAPEUTICS NV have?

LAVA THERAPEUTICS NV (LVTX) currently has 37 employees.


What are the support and resistance levels for LAVA THERAPEUTICS NV (LVTX) stock?

LAVA THERAPEUTICS NV (LVTX) has a support level at 1.1 and a resistance level at 1.44. Check the full technical report for a detailed analysis of LVTX support and resistance levels.


Is LAVA THERAPEUTICS NV (LVTX) expected to grow?

The Revenue of LAVA THERAPEUTICS NV (LVTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the LVTX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy LAVA THERAPEUTICS NV (LVTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LAVA THERAPEUTICS NV (LVTX) stock pay dividends?

LVTX does not pay a dividend.


When does LAVA THERAPEUTICS NV (LVTX) report earnings?

LAVA THERAPEUTICS NV (LVTX) will report earnings on 2025-05-19.


What is the Price/Earnings (PE) ratio of LAVA THERAPEUTICS NV (LVTX)?

LAVA THERAPEUTICS NV (LVTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.93).


What is the Short Interest ratio of LAVA THERAPEUTICS NV (LVTX) stock?

The outstanding short interest for LAVA THERAPEUTICS NV (LVTX) is 2.47% of its float. Check the ownership tab for more information on the LVTX short interest.


LVTX Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to LVTX. When comparing the yearly performance of all stocks, LVTX turns out to be only a medium performer in the overall market: it outperformed 44.19% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LVTX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LVTX. Both the profitability and financial health of LVTX have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LVTX Financial Highlights

Over the last trailing twelve months LVTX reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 41.51% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -33.16%
ROE -83.78%
Debt/Equity 0.18
Chartmill High Growth Momentum
EPS Q2Q%41.67%
Sales Q2Q%1313.6%
EPS 1Y (TTM)41.51%
Revenue 1Y (TTM)N/A

LVTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to LVTX. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of -48.34% and a revenue growth -100% for LVTX


Ownership
Inst Owners35.48%
Ins Owners0.52%
Short Float %2.47%
Short Ratio0.76
Analysts
Analysts78
Price Target1.87 (42.75%)
EPS Next Y-48.34%
Revenue Next Year-100%